Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Tjark, Reblin"'
Publikováno v:
The Journal of Sexual Medicine. 3:883-891
Introduction Erectile dysfunction (ED) affects up to 70% of men with diabetes, occurring with a higher prevalence in those with type 1 diabetes than with type 2 diabetes. Studies investigating treatment of ED in men with diabetes have largely been co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31c6fdd60b86dcc160e7853bd943ce2f
https://doi.org/10.1111/j.1743-6109.2006.00295.x
https://doi.org/10.1111/j.1743-6109.2006.00295.x
Autor:
Linda Fineder, Friedrich Thaiss, Gunter Wolf, Hans Dieplinger, Nicolette Donarski, Jan Hinrich Bräsen, Rolf A.K. Stahl, Tjark Reblin, Ulrike Beisiegel
Publikováno v:
American Journal of Kidney Diseases. 38:619-630
The sites and mechanisms of the catabolism of atherogenic lipoprotein(a) (Lp(a)) are not well understood. Lp(a) is increased in patients with end-stage renal disease, suggesting a renal catabolism of Lp(a). To gain a better insight into renal handlin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e1da1c01d577cb59222026a5605fe26
https://doi.org/10.1053/ajkd.2001.26889
https://doi.org/10.1053/ajkd.2001.26889
Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction
Autor:
Dan, Ziegler, Frank, Merfort, Hermann, Van Ahlen, Aksam, Yassin, Tjark, Reblin, Marcus, Neureither
Publikováno v:
The journal of sexual medicine. 3(5)
Erectile dysfunction (ED) affects up to 70% of men with diabetes, occurring with a higher prevalence in those with type 1 diabetes than with type 2 diabetes. Studies investigating treatment of ED in men with diabetes have largely been conducted in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f1e2bba207df3dd1a000de35201a00b4
https://pubmed.ncbi.nlm.nih.gov/16942532
https://pubmed.ncbi.nlm.nih.gov/16942532
Autor:
Hermann Van Ahlen, Aksam Yassin, Tjark Reblin, Klaus Wahle, Marcus Neureither, Wolfram Kupper
Publikováno v:
The journal of sexual medicine. 2(6)
Vardenafil, a phosphodiesterase type 5 (PDE5) inhibitor, was evaluated in a prospective trial in the primary care setting involving hypertensive men with ED who were receiving at least one antihypertensive medication.To investigate the safety and eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cf5fc2a7bc78fe5c6bde5e6ca374c6c
https://pubmed.ncbi.nlm.nih.gov/16422810
https://pubmed.ncbi.nlm.nih.gov/16422810
Publikováno v:
Atherosclerosis. 145(1)
Lipoprotein(a) [Lp(a)] is a risk factor for coronary heart disease (CHD) in particular in association with high low density lipoprotein (LDL) cholesterol concentrations. Hypertriglyceridemia on the other hand has been found to be associated with low
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a32019348998db949f756837b7e50256
https://pubmed.ncbi.nlm.nih.gov/10428297
https://pubmed.ncbi.nlm.nih.gov/10428297
Publikováno v:
Atherosclerosis. 113(2)
Several studies have analysed apo(a) quantitatively in arterial wall tissue derived from post mortem samples. The purpose of this study was a qualitative analysis of Lp(a) in fresh human arterial wall tissue. It was evaluated whether Lp(a) exists as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04589311ec9fbf544cd7f96a2fbdff83
https://pubmed.ncbi.nlm.nih.gov/7605357
https://pubmed.ncbi.nlm.nih.gov/7605357
Publikováno v:
Atherosclerosis. 94(2-3)
Lp(a) is an LDL-like lipoprotein which contains an additional apolipoprotein called apo(a). Apo(a) exhibits a significant size polymorphism and its size is inversely correlated with plasma Lp(a) levels. We investigated the distribution of different a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22e059139a8d13e3b3db4d440bc328cd
https://pubmed.ncbi.nlm.nih.gov/1385958
https://pubmed.ncbi.nlm.nih.gov/1385958
Autor:
Tjark Reblin
Publikováno v:
Canadian Medical Association Journal. 180:841-841
The recent commentary by Lorraine Lipscombe[1][1] gave the impression that the 10-study meta-analysis by Loke and colleagues yields a new finding that there might be an association between thiazolidinediones and an increased risk of fractures in wome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a80f17f5a2f0661408b8350c33c2e44
https://doi.org/10.1503/cmaj.1090005
https://doi.org/10.1503/cmaj.1090005
Autor:
Tjark Reblin, Ulrike Beisiegel, N. Meyer, Hans Dieplinger, Thomas E. Willnow, Andreas Niemeier, Heiner Greten
Publikováno v:
Atherosclerosis. 134:147
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab144b6653925612e2c917071edf17cf
https://doi.org/10.1016/s0021-9150(97)88783-7
https://doi.org/10.1016/s0021-9150(97)88783-7
Autor:
Gregory E. Powell, James Blowers, Carrie E. Pierce, Clark C. Freifeld, Tjark Reblin, John S. Brownstein, Harold Rodriguez, Phil J. Burstein, H.G. Bell, Jeffery L. Painter, Nabarun Dasgupta, Harry A. Seifert, Michele Thomas, J. Alan Menius
Publikováno v:
BASE-Bielefeld Academic Search Engine
Post-marketing safety surveillance primarily relies on data from spontaneous adverse event reports, medical literature, and observational databases. Limitations of these data sources include potential under-reporting, lack of geographic diversity, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40a880b6ba255a37f43e646cc4f251a2
http://link.springer.com/10.1007/s40264-015-0385-6
http://link.springer.com/10.1007/s40264-015-0385-6
